fda approved glp-1 gip medications 2025 First in class, best in class or a wild card: who will dominate the anti-obesity medication market? Indications for GLP-1/GIP RA Summary

Maine with $158 million

Early studies are encouraging, but its technically hard to combine peptides in a single formulation, since each has different stability requirements

This packaging also protects the medication from environmental factors like moisture, heat, or light, which can affect its effectiveness

This inflammation makes it harder for your body to use insulin properly, which in turn leads to even more fat and inflammation, creating a difficult cycle to break

Several states (e.g., North Carolina, California, Connecticut, Rhode Island, Michigan) have paused or proposed ending Medicaid coverage for GLP1 drugs for weight loss due to escalating costs, while continuing coverage for diabetes or cardiovascular risk indications